Under the action of the vaccine, the body creates its own antibodies and develops immunity to nicotine dependence. Drugs that had been tested previously required repeated costly injections. It was difficult to calculate the dose of the means, as the action of them was strictly individual.
The new vaccine will be a salvation for smokers who have experienced all existing coping options but have been defeated. According to statistics, about 80% of people who quit smoking were returning to their habit again.
Scientists are constantly looking for new ways of how to get the body to abandon nicotine addiction. Prior to the new drug, there were two types of vaccines: active and passive. The first type is an alien agent for human immunity, the body sees “azutchik” and produces antibodies against it. But the tiny nicotine molecule wasn’t embedded in the active vaccine. The second type is a passive vaccine from a whole complex of ready antibodies that are needed for the development of immunity.
Weill Cornell’s research department developed a third species, a genetic vaccine. Scientists engineered antibodies that neutralize nicotine and placed them in a virus that does not adversely affect humans. After interaction with the genetic vaccine, liver cells begin to produce their antibodies, and in large numbers.
Most importantly, only a very small portion of the poisonous nicotine reaches the smoker’s brain. As a result, a person will not get what he waits for from a cigarette, and without that pleasure the very meaning of this bad habit is lost. The vaccine can also be used as a preventive agent to prevent the occurrence of nicotine addiction.
In humans, the vaccine has not yet been tested, rats and primates are on the line, but the mice that participated in the experiment feel no worse than before it began.